Grifols’s valuation not attractive at 7x net debt/Ebitda 2022 and weak cash generation; better risk/return with others like Almirall
Morgan Stanley | Grifols (GRF) will hold its Investor Day on June 30. We expect to hear on the following main topics: (i) Estimates on plasma growth (both consensus and ourselves already expect 20-25% growth in 2022, above 2019 levels, and see little chance of increases in the numbers). (ii) Greater visibility on the new launches from Biotest, fibrinogen and IgM which could be delayed. (iii) Leverage (competitive disruption and the smaller contribution…









